Title variants
Languages of publication
Abstracts
In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, in particular, rifamycin derivatives (rifabutin, rifapentine, and a new benzoxazinorifamycin, KRM-1648), fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, moxifloxacin, and others), new macrolides (clarithromycin, azithromycin, roxithromycin), and others. In this review, I have mainly described the in vitro and in vivo activities of these drugs against Mycobacterium tuberculosis and atypical mycobacteria, especially Mycobacterium avium complex. In addition, therapeutic efficacy of these drugs in cases of clinical treatment of mycobacterial infections have also been briefly mentioned.
Discipline
Year
Volume
Issue
Pages
183-188
Physical description
Contributors
author
References
Document Type
REVIEW
Publication order reference
H.Tomioka, Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-7ec71213-7e58-3030-a42a-b8876cf9b51e